Tag Archives: Direct online Procurement

Guangdong Unifies Medical Device Listing Process for May 2025 Batch

GUANGZHOU — Guangdong Province has announced the standardization of its medical device listing process, aiming to streamline the procurement and management of medical consumables. The first batch of newly listed products for May 2025 has been published, marking a significant step toward a unified and transparent procurement system.

Policy Breakdown

Unified Listing Process: The Guangdong Provincial Medical Device Exchange Center has released the first batch of medical devices under the new unified listing process. This batch, designated as GDHCTYGW01-20250501, includes various medical consumables that have been reviewed and approved for inclusion in the provincial procurement system.
Operational Details: Companies can log in to the Guangdong Medical Device Procurement Subsystem using their CA certificates to view the listing results and manage distribution relationships. The new system ensures that all listed products are centrally managed under a unified catalog.
Implementation Timeline: The new listing process will be applied to all future batches, with the goal of creating a standardized and efficient procurement environment. The first batch of products will be available for contract transactions immediately, provided that distribution relationships are properly maintained.
Regulatory Requirements: To facilitate smooth transactions, companies are urged to complete distribution relationship maintenance as soon as possible. Detailed operational guidelines are available on the official website under “Member Services – Business Guidelines.”

Industry Impact

Efficiency Gains: The unified listing process is expected to reduce administrative burdens and improve the efficiency of medical device procurement for healthcare providers.
Market Transparency: Standardizing the listing process enhances transparency, making it easier for companies to navigate the procurement system and ensuring fair competition.
Quality Assurance: The centralized management of listed products ensures that only high-quality and compliant medical devices are procured, benefiting both healthcare providers and patients.

Looking Ahead
Stakeholders, including medical device manufacturers and healthcare institutions, should familiarize themselves with the new listing process and operational requirements. The long-term goal is to create a more efficient and transparent procurement environment, ultimately improving the quality and availability of medical devices in Guangdong.-China Health Reform Pulse

For detailed implementation guidelines and the full list of approved products, refer to the official announcements from the Guangdong Provincial Medical Device Exchange Center.

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1927162319360495616

Yunnan Implements Centralized Procurement for Biochemical Reagents

KUNMING — Yunnan Province has initiated a centralized procurement program for biochemical reagents, specifically targeting products related to sugar metabolism and other biochemical tests. The policy aims to streamline the procurement process, reduce costs, and ensure the availability of high-quality medical reagents across the region.

Policy Breakdown

Centralized Procurement: The policy mandates that selected products from the “Sugar Metabolism and Biochemical Reagent Centralized Procurement List” will be available for purchase through Yunnan’s Medical Security Information Platform.
Implementation Timeline: The centralized procurement will take effect on June 5, 2025, with a procurement cycle of two years.
Distribution and Contracting: Selected companies will be required to establish distribution relationships through the platform, signing tripartite agreements annually to clarify rights and responsibilities.
Non-Selected Products: Products not included in the centralized procurement list will follow the dynamic pricing and listing requirements outlined in the “Yunnan Province Medicines and Medical Consumables Dynamic Listing Plan” (Yun Medical Insurance [2022] No. 92).

Industry Impact

Cost Reduction: The centralized procurement model is expected to drive down costs for biochemical reagents, benefiting both healthcare providers and patients.
Market Consolidation: Companies that fail to secure a place in the centralized procurement list may face challenges in market access, while selected companies will gain a competitive edge.
Quality Assurance: The policy emphasizes the importance of quality control, ensuring that only high-standard products are procured through the centralized system.

Looking Ahead
Stakeholders, including reagent manufacturers and healthcare providers, should closely monitor the implementation of the centralized procurement policy. The long-term goal is to enhance the efficiency and transparency of the procurement process while maintaining high standards of medical supplies.-China Health Reform Pulse

For detailed implementation guidelines and the full procurement list, refer to the official announcements from the Yunnan Provincial Government Procurement and Disposal Center.

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=25515&CatalogId=3

Hunan Province Announces Complaint Handling for May 2025 Drug Listing Applications

Hunan Province’s Medical Security Administration has released a notice detailing the handling of complaints regarding the drug listing applications for new drugs, reference formulations, and approved drugs in May 2025. The announcement, published on May 27, 2025, reflects the province’s commitment to transparency and accountability in its pharmaceutical procurement process.

During the public display period of the application results, a total of five complaints were received. The handling opinions have been integrated into Hunan’s Medical Security Information Platform’s tender and procurement management system. Companies involved are required to check the complaint module for specific outcomes.

For products with reconfirmed price limits, companies must confirm the prices in the price linkage management module by 5:00 PM on May 30, 2025. Failure to do so will result in the products being included in the next round of reapplication. This strict timeline underscores the importance of prompt action by pharmaceutical companies to ensure compliance and avoid delays in market access.

Strategic Implications for Pharmaceutical Companies

The notice serves as a clear directive for pharmaceutical companies operating in Hunan Province. It highlights the need for vigilance during the application and public display periods, as well as the importance of timely response to any complaints or adjustments required by the regulatory authority.

For companies with products undergoing price reconfirmation, the deadline is a critical factor. Missing the deadline could lead to significant delays, potentially affecting market entry and revenue generation. Therefore, companies must prioritize efficient communication channels and ensure that their internal processes are aligned with the regulatory requirements.

Broader Context and Future Outlook

This policy reflects a broader trend in China’s pharmaceutical sector, where regulatory authorities are increasingly focusing on transparency and accountability in drug procurement. Hunan Province’s initiative is part of a nationwide effort to streamline the drug listing process and enhance the efficiency of the healthcare supply chain.

Looking ahead, pharmaceutical companies should expect continued scrutiny of their applications and a need for robust compliance mechanisms. The use of digital platforms for complaint handling and price confirmation also highlights the importance of technological proficiency in navigating the regulatory environment.-China Health Reform Pulse

Policy Source: http://ybj.hunan.gov.cn/ybj/first113541/firstF/f3113607/202505/t20250527_33684054.html